Pegaldesleukin

Drug Profile

Pegaldesleukin

Alternative Names: PEG interleukin-2; Proleukin-PEG™

Latest Information Update: 23 Feb 2004

Price : $50

At a glance

  • Originator Research Corporation Technologies
  • Developer Chiron Corporation; Eurocetus; Nonindustrial source; Research Corporation Technologies
  • Class Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer metastases; Head and neck cancer; HIV-1 infections; Prostate cancer

Most Recent Events

  • 23 Feb 2004 Discontinued - Clinical-Phase-Unknown for HIV-1 infections in France (IV)
  • 23 Feb 2004 Discontinued - Phase-I for Head and neck cancer in Netherlands (Intratumoural)
  • 23 Feb 2004 Discontinued - Phase-II for Cancer metastases in Netherlands (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top